Science Explorer Back to mapMap
Discussion
Company · Waltham · United States

Kala Pharmaceuticals (United States)

kalarx.comROR OpenAlex
Research works
40
▲ 65% vs 2018-21
Citations
1.1k
28.2 per fractional work
Top-10% rate
9.2%
all institutions 10.0%
Open access
36%
world 40%
International
29%
world 18%
Kala Pharmaceuticals (United States)

Not ranked overall: Kala Pharmaceuticals (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Kala Pharmaceuticals (United States) work in?

In all years, 46% of research at Kala Pharmaceuticals (United States) is in Life Sciences, 35% in Health Sciences. Its largest fields are Medicine (33%), Biochemistry, Genetics and Molecular Biology (29%), Pharmacology, Toxicology and Pharmaceutics (10%). It does 2.4× the world's share of Life Sciences.

Life Sciences: 18 fractional works · 45.9% of its workBiochemistry, Genetics and Molecular Biology: 11 fractional works · 28.9% of its workMolecular Biology: 7 fractional works · 18.7% of its workCancer Research: 1 fractional works · 3.4% of its workBiotechnology: 1 fractional works · 2.0% of its workCell Biology: 0 fractional works · 1.3% of its workBiophysics: 0 fractional works · 1.1% of its workClinical Biochemistry: 0 fractional works · 0.8% of its workGenetics: 0 fractional works · 0.7% of its workMolecular Medicine: 0 fractional works · 0.7% of its workBiochemistry: 0 fractional works · 0.3% of its workPharmacology, Toxicology and Pharmaceutics: 4 fractional works · 10.2% of its workPharmaceutical Science: 4 fractional works · 10.2% of its workNeuroscience: 1 fractional works · 3.4% of its workNeurology: 1 fractional works · 1.7% of its workCognitive Neuroscience: 0 fractional works · 0.8% of its workEndocrine and Autonomic Systems: 0 fractional works · 0.8% of its workImmunology and Microbiology: 1 fractional works · 3.3% of its workImmunology: 1 fractional works · 3.1% of its workApplied Microbiology and Biotechnology: 0 fractional works · 0.2% of its workAgricultural and Biological Sciences: 0 fractional works · 0.2% of its workPlant Science: 0 fractional works · 0.2% of its workHealth Sciences: 14 fractional works · 34.9% of its workMedicine: 13 fractional works · 33.4% of its workOncology: 2 fractional works · 6.1% of its workPulmonary and Respiratory Medicine: 2 fractional works · 5.9% of its workPublic Health, Environmental and Occupational Health: 2 fractional works · 5.7% of its workOphthalmology: 1 fractional works · 3.6% of its workRadiology, Nuclear Medicine and Imaging: 1 fractional works · 2.5% of its workPhysiology: 1 fractional works · 1.8% of its workPharmacology: 1 fractional works · 1.5% of its workHematology: 0 fractional works · 1.1% of its workEmergency Medicine: 0 fractional works · 1.0% of its workDermatology: 0 fractional works · 0.8% of its workPsychiatry and Mental health: 0 fractional works · 0.8% of its workEpidemiology: 0 fractional works · 0.4% of its workReproductive Medicine: 0 fractional works · 0.4% of its workSurgery: 0 fractional works · 0.4% of its workCritical Care and Intensive Care Medicine: 0 fractional works · 0.3% of its workGenetics: 0 fractional works · 0.3% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 0.2% of its workInfectious Diseases: 0 fractional works · 0.2% of its workRheumatology: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.2% of its workHealth Professions: 1 fractional works · 1.5% of its workRadiological and Ultrasound Technology: 0 fractional works · 0.8% of its workGeneral Health Professions: 0 fractional works · 0.6% of its workPhysical Sciences: 6 fractional works · 14.4% of its workEnvironmental Science: 2 fractional works · 4.5% of its workEcology: 1 fractional works · 2.5% of its workEnvironmental Engineering: 0 fractional works · 0.8% of its workGlobal and Planetary Change: 0 fractional works · 0.8% of its workPollution: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.0% of its workMaterials Science: 1 fractional works · 3.3% of its workMaterials Chemistry: 1 fractional works · 2.2% of its workBiomaterials: 0 fractional works · 0.8% of its workElectronic, Optical and Magnetic Materials: 0 fractional works · 0.2% of its workEngineering: 1 fractional works · 2.0% of its workBiomedical Engineering: 0 fractional works · 0.9% of its workMedia Technology: 0 fractional works · 0.8% of its workElectrical and Electronic Engineering: 0 fractional works · 0.3% of its workChemistry: 1 fractional works · 2.0% of its workPhysical and Theoretical Chemistry: 0 fractional works · 1.0% of its workOrganic Chemistry: 0 fractional works · 0.7% of its workSpectroscopy: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.1% of its workEarth and Planetary Sciences: 0 fractional works · 0.8% of its workGeochemistry and Petrology: 0 fractional works · 0.8% of its workComputer Science: 0 fractional works · 0.6% of its workComputational Theory and Mathematics: 0 fractional works · 0.4% of its workArtificial Intelligence: 0 fractional works · 0.2% of its workMathematics: 0 fractional works · 0.4% of its workStatistics and Probability: 0 fractional works · 0.4% of its workEnergy: 0 fractional works · 0.3% of its workRenewable Energy, Sustainability and the Environment: 0 fractional works · 0.3% of its workChemical Engineering: 0 fractional works · 0.3% of its workCatalysis: 0 fractional works · 0.3% of its workPhysics and Astronomy: 0 fractional works · 0.2% of its workSocial Sciences: 2 fractional works · 4.8% of its workEconomics, Econometrics and Finance: 1 fractional works · 1.5% of its workEconomics and Econometrics: 0 fractional works · 1.2% of its workFinance: 0 fractional works · 0.3% of its workSocial Sciences: 1 fractional works · 1.4% of its workEducation: 0 fractional works · 0.8% of its workGeneral Social Sciences: 0 fractional works · 0.3% of its workLibrary and Information Sciences: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.0% of its workDecision Sciences: 0 fractional works · 0.8% of its workManagement Science and Operations Research: 0 fractional works · 0.8% of its workPsychology: 0 fractional works · 0.8% of its workExperimental and Cognitive Psychology: 0 fractional works · 0.8% of its workArts and Humanities: 0 fractional works · 0.3% of its workConservation: 0 fractional works · 0.3% of its workALL ITS WORKKalaPharmaceuticals…40fractional works, all years
Life Sciences46%Physical Sciences14%Health Sciences35%Social Sciences5%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 22 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology1128.9%
    2. Pharmacology, Toxicology and Pharmaceutics410.2%
    3. Neuroscience13.4%
    4. Immunology and Microbiology13.3%
    5. Agricultural and Biological Sciences00.2%
    1. Medicine1333.4%
    2. Health Professions11.5%
    1. Environmental Science24.5%
    2. Materials Science13.3%
    3. Engineering12.0%
    4. Chemistry12.0%
    5. Earth and Planetary Sciences00.8%
    6. Computer Science00.6%
    7. Mathematics00.4%
    8. Energy00.3%
    9. Chemical Engineering00.3%
    10. Physics and Astronomy00.2%
    1. Economics, Econometrics and Finance11.5%
    2. Social Sciences11.4%
    3. Decision Sciences00.8%
    4. Psychology00.8%
    5. Arts and Humanities00.3%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.16× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 6.70× its world share, 4 worksBiochemistry, Geneti…Immunology and Microbiology: 7.10× its world share, 1 worksImmunology and Micro…Neuroscience: 2.83× its world share, 0 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 3.91× its world share, 0 worksPharmacology, Toxico…Computer Science: 0.10× its world share, 0 worksComputer ScienceEnvironmental Science: 0.62× its world share, 0 worksEnvironmental ScienceMathematics: 1.30× its world share, 0 worksMathematicsPhysics and Astronomy: 0.28× its world share, 0 worksPhysics and AstronomyHealth Professions: 0.87× its world share, 0 worksHealth ProfessionsMedicine: 1.91× its world share, 4 worksMedicineDecision Sciences: 3.17× its world share, 0 worksDecision SciencesEconomics, Econometrics and Finance: 1.07× its world share, 0 worksEconomics, Econometr…1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 7.1×. Every wedge is a field page.

All 13 fields, with their numbers
  1. Immunology and Microbiology7.10×1 works
  2. Biochemistry, Genetics and Molecular Biology6.70×4 works
  3. Pharmacology, Toxicology and Pharmaceutics3.91×0 works
  4. Decision Sciences3.17×0 works
  5. Neuroscience2.83×0 works
  6. Medicine1.91×4 works
  7. Mathematics1.30×0 works
  8. Economics, Econometrics and Finance1.07×0 works
  9. Health Professions0.87×0 works
  10. Environmental Science0.62×0 works
  11. Physics and Astronomy0.28×0 works
  12. Agricultural and Biological Sciences0.16×0 works
  13. Computer Science0.10×0 works

Who are the top researchers at Kala Pharmaceuticals (United States)?

Ranked on the quality score, Alexey Popov lead among researchers whose main affiliation is Kala Pharmaceuticals (United States).

  1. 1 Alexey Popov United States · #2,196,343 worldwide 302 citations · 17 works
All ranked researchers at Kala Pharmaceuticals (United States)

What are the most cited papers from Kala Pharmaceuticals (United States)?

The most cited paper from Kala Pharmaceuticals (United States) is "β-Lactams and β-Lactamase Inhibitors: An Overview" (Karen Bush, Patricia A. Bradford, 2016), with 1,364 citations. Next come "Mucus-Penetrating Particles and the Role of Ocular Mucus as a Barrier to Micro- and Nanosuspensions" (80) and "Topical Ocular Drug Delivery to the Back of the Eye by Mucus-Penetrating Particles" (78).

Most cited papers
#PaperReleasedCitations
1 β-Lactams and β-Lactamase Inhibitors: An Overview Karen Bush, Patricia A. Bradford · Cold Spring Harbor Perspectives in Medicine Open access 21 Jun 2016 1,364
2 Mucus-Penetrating Particles and the Role of Ocular Mucus as a Barrier to Micro- and Nanosuspensions Alexey Popov · Journal of Ocular Pharmacology and Therapeutics Open access Jul 2020 80
3 Topical Ocular Drug Delivery to the Back of the Eye by Mucus-Penetrating Particles Lisa R. Schopf, Alexey M. Popov, Elizabeth M. Enlow et al. · Translational Vision Science & Technology Open access 11 Jun 2015 78
4 Mucus-penetrating nanoparticles made with “mucoadhesive” poly(vinyl alcohol) Alexey Popov, Elizabeth Enlow, James L. Bourassa et al. · Nanomedicine Nanotechnology Biology and Medicine 30 Apr 2016 70
5 Recent developments in ocular drug delivery Hongming Chen · Journal of drug targeting 14 Sep 2015 68
All 31 most cited papers, with filters and sorting

Which keywords describe research at Kala Pharmaceuticals (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Nanoparticles, Drug Delivery, Cancer Therapy, Chitosan, Mucosal, Cancer, Dry Eye Disease and Ocular Surface.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 37 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 37 words, with their numbers
  1. Nanoparticles5▲ 9.8×8 topics
  2. Drug Delivery3▲ 17×2 topics
  3. Cancer Therapy3▲ 12×6 topics
  4. Cancer3▲ 5.2×9 topics
  5. Chitosan3▲ 132×1 topic
  6. Mucosal3▲ 261×1 topic
  7. Epidemiology3▲ 1.79×6 topics
  8. Inflammation2▲ 2.2×6 topics
  9. Dry Eye Disease2▲ 139×1 topic
  10. Ocular Surface2▲ 139×1 topic
  11. Glycosylation2▲ 20×2 topics
  12. Antibiotic Resistance2▲ 11×5 topics
  13. Gene Expression2▲ 7.0×4 topics
  14. Tumor Microenvironment2▲ 13×5 topics
  15. Oxidative Stress2▲ 2.2×8 topics
  16. Transcriptional Regulation2▲ 15×2 topics
  17. Breast Cancer1▲ 12×3 topics
  18. Epigenetic Regulation1▲ 17×2 topics
  19. Neurodegeneration1▲ 11×3 topics
  20. BET Bromodomains1▲ 162×1 topic
  21. HDAC Inhibitors1▲ 164×1 topic
  22. Histone Deacetylases1▲ 164×1 topic
  23. Immunotherapy1▲ 5.1×6 topics
  24. PROTACs1▲ 162×1 topic
  25. Metabolism1▲ 4.6×2 topics
  26. Therapeutics1▲ 21×2 topics
  27. Gene Therapy1▲ 11×2 topics
  28. Glycans1▲ 34×1 topic
  29. Immune System1▲ 8.6×1 topic
  30. Neuroinflammation1▲ 9.8×2 topics
  31. Tumor Targeting1▲ 21×2 topics
  32. CDK4/6 Inhibitors1▲ 165×1 topic
  33. Immunity1▲ 7.5×2 topics
  34. Monoclonal Antibodies1▲ 18×2 topics
  35. Palbociclib1▲ 165×1 topic
  36. Therapeutic Antibodies1▲ 20×2 topics
  37. Tumor Regression1▲ 29×2 topics

Which research topics does Kala Pharmaceuticals (United States) publish most on?

By volume in 2022-now: Advanced Breast Cancer Therapies, Cancer Research and Treatments, Glycosylation and Glycoproteins Research and Immune cells in cancer.

Advanced Breast Cancer Therapies: 1 fractional worksCancer Research and Treatments: 1 fractional worksGlycosylation and Glycop…1Glycosylation and Glycoproteins Research: 1 fractional worksImmune cells in cancer1Immune cells in cancer: 1 fractional worksProtein Degradation and Inhibitors: 0 fractional worksAcute Myeloid Leukemia Research: 0 fractional worksCancer Immunotherapy and…0Cancer Immunotherapy and Biomarkers: 0 fractional worksNeuroinflammation and Neurodegeneration Mechanisms: 0 fractional worksCancer, Hypoxia, and Metabolism: 0 fractional worksCancer-related Molecular Pathways: 0 fractional works
Pulmonary and Respiratory MedicineBiotechnologyMolecular BiologyImmunology4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 1 works
  2. 2 Cancer Research and Treatments Biotechnology 1 works
  3. 3 Glycosylation and Glycoproteins Research Molecular Biology 1 works
  4. 4 Immune cells in cancer Immunology 1 works
  5. 5 Protein Degradation and Inhibitors Molecular Biology 0 works
  6. 6 Acute Myeloid Leukemia Research Hematology 0 works
  7. 7 Cancer Immunotherapy and Biomarkers Oncology 0 works
  8. 8 Neuroinflammation and Neurodegeneration Mechanisms Neurology 0 works
  9. 9 Cancer, Hypoxia, and Metabolism Cancer Research 0 works
  10. 10 Cancer-related Molecular Pathways Oncology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available35.8%not open64.2%

World: 40% of research is openly available.

with international co-authors28.7%domestic only71.3%

World: 18% is written across borders.

How has Kala Pharmaceuticals (United States)'s research output changed?

Output in 2022-2025 was 65% higher than in 2018-2021.

still counting1990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Kala Pharmaceuticals (United States) as a percentage of every work published that year, 0.000046% in 2024.

still counting0.00010%0.00020%0.00030%Kala Pharmaceuticals (United States)0.000043% in 20251990200020102020

Fractional works of Kala Pharmaceuticals (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Waltham

All research institutions in Waltham

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Kala Pharmaceuticals (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.